Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis

Experimental Neurology

Volumn 155, Issue 2, 1999, Pages 243-251

  Barnéoud, Pascal ^a   Curet, Olivier ^a  

^a SANOFI   (France)

Author keywords

Antioxidant; Aspirin; Behavior; Neuroprotection; Transgenic mice

Indexed keywords

ACETYLSALICYLIC ACID; LYSINE ACETYLSALICYLATE; RILUZOLE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL BEHAVIOR; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; COORDINATION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG POTENCY; DRUG SOLUBILITY; DRUG TOLERABILITY; GENE MUTATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARALYSIS; PRIORITY JOURNAL; REFLEX; TRANSGENIC MOUSE;

EID: 0344609220     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6984     Document Type: Article

References (44)

1. Andrus P. K., Fleck T. J., Himes C. S., Gurney M. E., Hall E. D. Measurement of spinal cord lipid and protein oxidation in the transgenic mouse model of familial amyotrophic lateral sclerosis. Soc. Neurosci. Abs. 23:1997;729.12.
2. Aubin N., Carter C., Deffois A., Curet O. Aspirin and salicylate protect against MPTP induced dopamine depletion in mice. J. Neurochem. 1998.
3. Azzouz M., Leclerc N., Gurney M., Warter J. M., Poindron P., Borg J. Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis. Muscle Nerve. 20:1997;45-51.
4. Barnéoud P., Lolivier J., Sanger D. J., Scatton B., Moser P. Quantitative motor assessment in FALS mice: A longitudinal study. Neuroreport. 8:1997;2861-2865.
5. Beal M. F., Ferrante R. J., Browne S. E., Matthews R. T., Kowall N. W., Brown R. H. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 69:1997;646-654.
6. Beckman J. S., Carson M., Smith C. D., Koppenol W. H. ALS, SOD and peroxynitrite. Nature. 364:1993;584.
7. Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330:1994;585-591.
8. Bowling A. C., Schulz G. B., Brown R. H. J., Beal M. F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. 61:1993;2322-2325.
9. Brown R. H. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell. 80:1995;687-692.
10. Bruijn L. I., Beal M. F., Becher M. W., Schulz J. B., Wong P. C., Price D. L., Cleveland D. W. Elevated free nitrotyrosine levels, but not protein-bond nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrantin vivo. Proc. Natl. Acad. Sci. USA. 94:1997;7606-7611.
11. Cederbaum J. M. The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rhCNTF) in patients with amyotrophic lateral sclerosis: Relationship to parameters of the acute phase response. Clin. Neuropharmacol. 18:1995;500-514.
12. Cederbaum J. M. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. Clin. Neuropharmacol. 18:1995;515-532.
13. Chiu A. Y., Zhai P., Dal Canto M. C., Peters T. M., Kwon Y. W., Prattis S. M., Gurney M. E. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol. Cel. Neurosci. 6:1995;349-362.
14. Chiueh C. C., Krishna G., Tulsi P., Obata T., Lang K., Huang S. J., Murphy D. L. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: Effects of MPP+. Free Rad. Biol. Med. 13:1992;581-583.
15. Cleveland D. W., Bruijn L. I., Wong P. C., Marszalek J. R., Vechio J. D., Lee M. K., Xu X. S., Borchelt D. R., Sisodia S. S., Price D. L. Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease. Neurology. 47:1996;S54-S61.
16. de Medinaceli L., Freed W. J., Wyatt R. J. An indexed of the functional condition of rat sciatic nerve based on measurements made from walding tracks. Exp. Neurol. 77:1982;634-643.
17. Deng H. X., Hentati A., Tainer J. A., Iqbal Z., Cayabyab A., Hung W. Y., Getzoff E. D., Hu P., Merzfeldt B., Roos R. P., Warner C. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science. 261:1993;1047-1051.
18. Ferrante R. J., Browne S. E., Shinobu L. A., Bowling A. C., Baik M. J., MacGarvey U., Kowall N. W., Brown R. H. Jr., Beal M. F. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69:1997;2064-2074.
19. Festoff B. W. Amyotrophic lateral sclerosis. Drugs. 51:1996;28-44.
20. Friedlander R. M., Brown R. H., Gagliardini V., Wang J., Yuan J. Inhibition of ICE slows ALS in mice. Nature. 388:1997;31.
21. Ghadge G. D., Lee J. P., Bindokas V. P., Jordan J., Ma L., Miller R. J., Roos R. P. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: Molecular mechanisms of neuronal death and protection. J. Neurosci. 17:1997;8756-8766.
22. κ. Science. 274:1996;1383-1385.
23. Gurney M. E. Transgenic animal models of familial amyotrophic lateral sclerosis. J. Neurol. 244:1997;S15-S20.
24. Gurney M. E., Cutting F. B., Zhai P., Doble A., Taylor C. P., Andrus P. K., Hall E. D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39:1996;147-157.
25. Gurney M. E., Pu H., Mauro C., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., Caliendo J., Hentati A., Kwon Y. W., Deng H. X., Chen W., Zhai P., Sufit R. L., Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 264:1994;1772-1775.
26. Hirano A. Cytopathology in amyotrophic lateral sclerosis. Adv. Neurol. 56:1991;91-101.
27. Hottinger A. F., Fine E. G., Gurney M. E., Zurn A. D., Aebischer P. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci. 9:1997;1548-1551.
28. Kennel P. F., Finiels F., Revah F., Mallet J. Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: An electromyographic study. Neuroreport. 8:1996;1427-1431.
29. Kerasidis H., Wrathall J. R., Gale K. Behavioral assessment of functional deficit in rats with contusive spinal cord injury. J. Neurosci. Meth. 20:1987;167-189.
30. Kostic V., Jackson-Lewis V., de Bilbao F., Dubois-Dauphin M., Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science. 277:1997;559-562.
31. Kwon G., Hill J. R., Corbett J. A., McDaniel M. L. Effects of aspirin on nitric oxide formation andde novo. Mol. Pharmacol. 52:1997;398-405.
32. Lacomblez L., Bensimon G., Leigh P. N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 347:1996;1425-1431.
33. Mitchell J. A., Akarasereenont P., Thiemermann C., Flower R. J., Vane J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA. 90:1994;11693-11697.
34. Mitsumoto H., Ikeda K., Klinkosz B., Cedarbaum J. M., Wong V., Lindsay R. M. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science. 265:1994;1107-1110.
35. Oostveen J. A., Gurney M. E., Hall E. D. Immunocytochemical evidence of spinal cord lipid peroxidation, peroxynitrite formation, and astrocyte and microglial activation in the transgenic model of familial amyotrophic lateral sclerosis. Soc. Neurosci. Abs. 23:1997;729.13.
36. Ripps M. E., Huntley G. W., Hof P. R., Morrison J. H., Gordon J. W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 92:1995;689-693.
37. Rosen D. R., Siddique T., Patterson D., Figlewicz D. A., Sapp P., Hentati A., Donaldson D., Gotto J., O'Regan J. P., Deng H. X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S. M., Berger R., Tanzi R. E., Halperin J. J., Herzfeldt B., Van den Bergh R., Hung W., Bird T., Deng G., Mulder D. W., Smyth C., Laing N. G., Soriano E., Pericak-Vance M., Haines J., Rouleau G. A., Gusella J. S., Horvitz H. R., Brown R. H. Jr. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62.
38. Rothstein J. D. Therapeutic horizons for amyotrophic lateral sclerosis. Curr. Opin. Neurobiol. 6:1996;679-687.
39. Rothstein J. D., Martin L. J., Kuncl R. W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 236:1992;1464-1468.
40. Sagot Y., Tan S. A., Baetge E., Schmalbruch H., Kato A. C., Aebischer P. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuropathy in the mouse. Eur. J. Neurosci. 7:1995;1313-1322.
41. Sendtner M., Schmalbruch H., Stockli K. A., Carroll P., Kreutzberg G. W., Thoenen H. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy (see comments). Nature. 358:1992;502-504.
42. Wiedau-Pazos M., Goto J. J., Rabizadeh S., Gralla E. B., Roe J. A., Lee M. K., Valentine J. S., Bredesen D. E. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science. 271:1996;515-518.
43. Wong P. C., Pardo C. A., Borchelt D. R., Lee M. K., Copeland N. G., Jenkins N. A., Sisodia S. S., Cleveland D. W., Price D. L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 14:1995;1105-1116.
44. mfor hydrogen peroxide. Proc. Natl. Acad. Sci. USA. 93:1996;5709-5714.